NCT00800618View on ClinicalTrials.gov

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Endometriosis
Interventions
DRUG

PF-02413873 100 mg QD

100 mg of PF-02413873 oral suspension once daily for 14 days

DRUG

PF-02413873 1500 mg QD

1500 mg of PF-02413873 oral suspension once daily for 14 days

DRUG

PF-02413873 20 mg QD

20 mg of PF-02413873 oral suspension once daily for 14 days

DRUG

PF-02413873 500 mg QD

500 mg of PF-02413873 oral suspension once daily for 14 days

DRUG

PF-02413873 Placebo

PF-0241383 Placebo once daily for 14 days

Trial Locations (4)

1070

Pfizer Investigational Site, Brussels

66211

Pfizer Investigational Site, Overland Park

66212

Pfizer Investigational Site, Overland Park

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00800618 - A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women | Biotech Hunter | Biotech Hunter